The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an In Vitro Pharmacokinetic-Pharmacodynamic Model
- 18 March 2021
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 65 (4)
- https://doi.org/10.1128/aac.01292-20
Abstract
Background. Posaconazole is more in vitro active against Candida albicans than fluconazole and approved for the treatment of oropharyngeal candidiasis but not invasive candidiasis (IC). We explored the efficacy of posaconazole against C. albicans in an in vitro pharmacokinetic-pharmacodynamic (PK-PD) model of IC and determined the probability of pharmacodynamic target attainment for the oral solution (o.s.) and i.v./tablet formulations. Methods. Three clinical C. albicans isolates (posaconazole MICs 0.008-0.25 mg/liter) were studied in the in vitro PK-PD dilution model simulating steady state posaconazole PK. The in vitro exposure-effect relationship fAUC0-24/MIC was described and compared with in vivo outcome in animals with IC. PK-PD susceptibility breakpoints and trough levels required for optimal treatment were determined for EUCAST and CLSI24h/48h methods, using the fAUC0-24/MIC associated with half-maximal activity (EI50) and Monte Carlo simulation analysis for o.s. (400 mg q12h) and i.v./tablet formulations (300 mg q24h). Results. The in vitro mean (95%CI) EI50 was 330 (183-597) fAUC0-24/MIC for CLSI24h and 169 (92-310) for EUCAST/CLSI48h methods, which are close to the near-stasis in vivo effect. The probability of target attainment for EI50 was estimated and for the wild-type isolates (MIC ≤ 0.06 mg/liter) it was low for the o.s. and higher than 95% for the i.v./tablet formulations for the EUCAST/CLSI48h but not for CLSI24h method. Non-wild-type isolates with EUCAST/CLSI48h MICs 0.125 and 0.25 mg/liter would require trough levels >1.2 and >2.4 mg/liter, respectively. Conclusion. Posaconazole i.v./tablet formulations may have a role in the therapy of invasive infections by wild-type C. albicans isolates provided a steady state is reached fast. A PK-PD susceptibility breakpoint at the ECOFF of 0.06 mg/liter was determined.Funding Information
- European Society of Clinical Microbiology and Infectious Diseases
This publication has 29 references indexed in Scilit:
- Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic modelJournal of Antimicrobial Chemotherapy, 2019
- Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with NeutropeniaAntimicrobial Agents and Chemotherapy, 2014
- Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal DiseaseAntimicrobial Agents and Chemotherapy, 2014
- Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012Journal of Clinical Microbiology, 2012
- EUCAST technical note on posaconazole*Clinical Microbiology & Infection, 2011
- Posaconazole: when and how? The clinician’s viewMycoses, 2011
- In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and YeastsAntimicrobial Agents and Chemotherapy, 2006
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Pharmacodynamics of a New Triazole, Posaconazole, in a Murine Model of Disseminated CandidiasisAntimicrobial Agents and Chemotherapy, 2004
- Changes in susceptibility to posaconazole in clinical isolates of Candida albicansJournal of Antimicrobial Chemotherapy, 2003